Neurogene Inc. (NGNE)
NASDAQ: NGNE · IEX Real-Time Price · USD
29.96
+0.09 (0.30%)
Apr 26, 2024, 4:00 PM EDT - Market closed
Company Description
Neurogene Inc., a biotechnology company, develops genetic medicines for rare neurological diseases.
The company's product candidates include NGN-401 which is packaged in an adeno-associated virus 9 that is in Phase 1/2 clinical trial for the treatment of Rett syndrome; and NGN-101, a conventional gene therapy candidate that is in Phase 1/2 clinical trial to treat CLN5 Batten disease.
It has a license agreement with The University of North Carolina, the University of Edinburgh, Virovek, Inc., and Sigma-Aldrich Co. LLC.
The company is headquartered in New York, New York.
Neurogene Inc.
| Country | United States |
| Founded | 2003 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 91 |
| CEO | Dr. Rachel L. McMinn Ph.D. |
Contact Details
Address: 535 W 24th Street, 5th Floor New York, New York 10011 United States | |
| Phone | (877) 237-5020 |
| Website | neurogene.com |
Stock Details
| Ticker Symbol | NGNE |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001404644 |
| ISIN Number | US64135M1053 |
| Employer ID | 98-0542593 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Rachel L. McMinn Ph.D. | Founder, Chief Executive Officer and Director |
| Christine Mikail Cvijic J.D. | President, Chief Financial Officer and Secretary |
| Arvind Sreedharan | Senior Vice President of Business Operations |
| Dr. Stuart Cobb Ph.D. | Chief Scientific Officer |
| Donna M. Cochener-Metcalfe J.D. | Senior Vice President and General Counsel |
| Dr. Effie Albanis M.D. | Senior Vice President of Early Clinical and Translational Research |
| Dr. Andrew E. Mulberg CPI, FAAP, M.D. | Senior Vice President of Regulatory Affairs, Quality Assurance and Quality Control |
| Ricardo Jimenez | Senior Vice President of Technical Operations |
| Dr. Albena Patroneva M.B.A., M.D. | Senior Vice President of Clinical Development |
| Dr. Julie Jordan M.D. | Chief Medical Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 26, 2024 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Apr 26, 2024 | ARS | Filing |
| Apr 26, 2024 | DEF 14A | Other definitive proxy statements |
| Apr 25, 2024 | 8-K | Current Report |
| Apr 22, 2024 | 8-K | Current Report |
| Apr 2, 2024 | 8-K | Current Report |
| Mar 18, 2024 | 8-K | Current Report |
| Mar 18, 2024 | 10-K | Annual Report |
| Mar 7, 2024 | 144 | Filing |
| Mar 4, 2024 | 144 | Filing |